Press Release August 8, 2017

Fresenius Medical Care to Acquire NxStage Medical in $2 Billion Deal

Alston & Bird’s Food, Drug & Device/FDA Group helped advise Fresenius Medical Care North America in an agreement by Fresenius Medical Care AG & Co., the world’s largest provider of dialysis products and services, to acquire NxStage Medical, Inc., a leading home dialysis device maker. The Alston & Bird team provided assistance with U.S. Food and Drug Administration and related regulatory due diligence as part of the transaction, which is valued at approximately $2 billion.

NxStage produces products aimed at the treatment of end-stage renal disease and acute kidney failure. The company, which is headquartered in Lawrence, MA, and listed on the Nasdaq, posted revenues of $366 million in 2016.

The Alston & Bird regulatory team advising on the transaction was led by partner Julie Tibbets, working closely with associate Justin Mann, senior associate Brendan Carroll, and attorney Caitlin Hosmer.
Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222
This website uses cookies to improve functionality and performance. By continuing to browse this site, you are consenting to the use of cookies on this website. For details, see our Privacy Statement